Browse CXCL11

Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemotactic for interleukin-activated T-cells but not unstimulated T-cells, neutrophils or monocytes. Induces calcium release in activated T-cells. Binds to CXCR3. May play an important role in CNS diseases which involve T-cell recruitment. May play a role in skin immune responses.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006140 regulation of nucleotide metabolic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0009150 purine ribonucleotide metabolic process
GO:0009187 cyclic nucleotide metabolic process
GO:0010522 regulation of calcium ion transport into cytosol
GO:0010524 positive regulation of calcium ion transport into cytosol
GO:0010818 T cell chemotaxis
GO:0010959 regulation of metal ion transport
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0040017 positive regulation of locomotion
GO:0043270 positive regulation of ion transport
GO:0043949 regulation of cAMP-mediated signaling
GO:0043950 positive regulation of cAMP-mediated signaling
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0048247 lymphocyte chemotaxis
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051272 positive regulation of cellular component movement
GO:0051279 regulation of release of sequestered calcium ion into cytosol
GO:0051281 positive regulation of release of sequestered calcium ion into cytosol
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0070098 chemokine-mediated signaling pathway
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0090279 regulation of calcium ion import
GO:0090280 positive regulation of calcium ion import
GO:0097553 calcium ion transmembrane import into cytosol
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1902656 calcium ion import into cytosol
GO:1903169 regulation of calcium ion transmembrane transport
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:1904427 positive regulation of calcium ion transmembrane transport
GO:2000021 regulation of ion homeostasis
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008009 chemokine activity
GO:0008201 heparin binding
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
GO:0048248 CXCR3 chemokine receptor binding
GO:1901681 sulfur compound binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CXCL11 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23843024Breast CarcinomaPromote immunity (T cell function)Furthermore, Stat1-deficiency resulted in reduced expression of the T-cell chemotactic factors CXCL9, CXCL10, and CXCL11 in the tumor epithelium.
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4590.512
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5090.741
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4110.713
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1610.863
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3380.822
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8080.599
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.1810.115
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5390.205
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7640.568
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0620.181
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6620.476
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8210.0181
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL11
Namechemokine (C-X-C motif) ligand 11
Aliases H174; b-R1; I-TAC; IP-9; SCYB9B; SCYB11; small inducible cytokine subfamily B (Cys-X-Cys), member 11; IP9; b ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.